Main Menu

Translational Epigenetics Team

Dr Andrew Feber’s Team focuses on the role changes in the epigenome play in cancer development and how these changes can be used as biomarkers to improve early cancer detection, diagnosis and the monitoring of response to therapy.

Team leader

Dr Andrew Feber

Dr Andrew Feber

Team Leader

Dr Andy Feber leads the Translational Epigenetic group at the ICR, he is also Deputy Director of clinical genomics at The Royal Marsden, NHS Foundation Trust. His research focuses on the role changes in the epigenome play in cancer development and how these changes can be used as biomarkers to improve early cancer detection, diagnosis and the monitoring of response to therapy.

ORCID 0000-0001-5282-0498

Team members

Dr Ron Finn

Bioinfomatician +44 20 7153 5280